<DOC>
	<DOCNO>NCT01805531</DOCNO>
	<brief_summary>National , multicenter , prospective , observational , non-interventional study . The objective determine switch Vitamin K antagonist ( VKA ) Xarelto subject treat VKA issue stroke prevention non valvular atrial fibrillation associate improvement treatment satisfaction 3 month . The treatment satisfaction measure Anti Clot Treatment Scale ( ACTS ) score .</brief_summary>
	<brief_title>Satisfaction/Quality Life With Rivaroxaban SPAF ( Stroke Prevention Atrial Fibrillation ) Indication</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Female male subject â‰¥ 18 year age diagnosis nonvalvular atrial fibrillation Who treat Vitamin K antagonist ( VKA ) issue least 4 previous week ( issue assess medical judgment ) Who start treatment rivaroxaban prevent stroke nonCNS ( central nervous system ) systemic embolism With anticoagulation therapy plan least 6 month Contra indication use Xarelto describe Summary Product Characteristics ( SmPC ) ; key contra indication : Hypersensitivity active substance excipients list SmPC section 6.1 . Lesion condition significant risk major bleed Concomitant treatment anticoagulant agent Clinically significant active bleeding Hepatic disease associate coagulopathy clinically relevant bleeding risk include cirrhotic patient Child Pugh B C Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>SF36 questionnaire</keyword>
	<keyword>Anti Clot Treatment Scale</keyword>
	<keyword>Satisfaction</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Stroke prevention</keyword>
</DOC>